For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to
therapeutic strategies based on personalized medicine owing to the complexity of designing …

More than 50 years after the discovery of RAS family proteins, which harbor the most
common activating mutations in cancer, the US Food and Drug Administration approved the …

Lung cancer is the most frequent cancer with an aggressive clinical course and high
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …

KRAS mutations are the most frequent gain-of-function alterations in patients with lung
adenocarcinoma (LADC) in the Western world. Although they have been identified decades …

Lung cancer remains the leading cause of cancer-related deaths worldwide. However,
significant progress has been made individualizing therapy based on molecular aberrations …

The KRAS mutation remains the most common driver mutation in patients with non-small cell
lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation …

Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that
drives tumorigenesis and has the ability to alter the immune system and the tumor immune …

Purpose: KRAS-mutant lung cancers have been recalcitrant to treatments including those
targeting the MAPK pathway. Covalent inhibitors of KRAS p. G12C allele allow for direct and …

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to
clinical development—a narrative review - PMC Back to Top Skip to main content NIH NLM …

Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …